Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Medical device makerLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in IsraelLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 2 spellings of its name, each linked to the record.
As of Nov 21, 2026, FDA's public records list Insightec and its 1 subsidiaries with 4 510(k) clearances. The most recent is a 510(k) clearance dated Oct 30, 2023: Exablate Model 2100V1, Exablate Prostate System, Exablate MRgFUS, Exablate 2100V1 Type 3.0.
Group recordsLabelled by a language model (which subsidiaries belong to the group) from the firm's FDA names. It is not an FDA field.: 4, 2 entities
510(k) clearances: 4
Records by year
Drug approvals, 510(k) clearances, recalls and letters, 2021 to 2026 to date, Insightec and its 1 subsidiaries
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
120212021Records1
20222022Records0vs 2021−1
120232023Records1vs 2022+1
20242024Records0vs 2023−1
20252025Records0vs 2024+0
20262026 to dateRecords0
Latest records
Newest first across sources; each opens the record
15 trials since 2013, 0 ongoing, by the sponsor of the products; see every authorized trial
A phase 2a, open-label, single-arm clinical trial of oral CNM-AU8 coupled with primary motor cortex blood-brain barrier…Feb 2, 2023 · Pending · Perflutren / CNM-AU8
A phase I/II study for bilateral putamenal delivery of recombinant glucocerebrosidase in patients with Parkinson's…Oct 28, 2022 · Pending · Perflutren / Imiglucerase
A pivotal study to evaluate the safety and effectiveness of exablate model 4000 using microbubble resonators to…Jun 23, 2022 · Pending · Perflutren
A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using exablate…Jun 23, 2022 · Pending · Perflutren /pembrolizumab
A safety and feasibility study to evaluate blood brain barrier disruption using mr-guided focused ultrasound in…Oct 29, 2021 · Pending · Definity (perflutren) / Doxorubicin
A study to evaluate the safety and feasibility of mr-guided focused ultrasound and pembrolizumab treatments for brain…Sep 9, 2021 · Pending · Definity (perflutren) / Pembrolizumab
Assessment of safety and feasibility of exablate neuro system to perform echo-focusing echo imaging in patients with…Jul 8, 2021 · Pending · Definity (perflutren)
Assessment of safety and feasibility of exablate blood-brain barrier disruption (BBBD) with microbubbles for the…May 15, 2020 · Closed · Carboplatin / Perflutren
Payments to doctors (Open Payments)
What 2 reporting entities in this group reported paying US doctors and teaching hospitals each year, $17.6M of it for research; see every company
$4.2M20192019Paid$4.2M
$4.6M20202020Paid$4.6Mvs 2019+$356K
$8.5M20212021Paid$8.5Mvs 2020+$3.9M
$5.1M20222022Paid$5.1Mvs 2021−$3.4M
$5.1M20232023Paid$5.1Mvs 2022−$28K
$5.0M20242024Paid$5.0Mvs 2023−$98K
$2.5M20252025Paid$2.5Mvs 2024−$2.5M
Device approvals in Japan (PMDA)
3 approvals since 2007, 1 of them new devices, matched by the Japanese company's name; see all Japanese device approvals
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.